How India Exports Gemcitabine to the World

In the United States, gemcitabine is approved for various oncological indications. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for gemcitabine, indicating a competitive generic market. Notably, on July 1, 2025, the FDA granted orphan drug designation to gemcitabine liposome injection for the treatment of biliary tract carcinomas, as per the FDA's Orphan Drug Designations and Approvals database. This designation provides incentives like tax credits and market exclusivity to encourage the development of treatments for rare diseases. The substantial number of Indian exporters (248) underscores India's significant role in supplying gemcitabine to the U.S. market.

In the European Union, gemcitabine is authorized for use in various cancer treatments. The European Medicines Agency (EMA) has harmonized the product information for gemcitabine-containing medicines to ensure consistent safety and efficacy information across member states. This harmonization process was completed in September 2008, as detailed in the EMA's referral procedure documentation. Manufacturers exporting to the EU must comply with Good Manufacturing Practice (GMP) standards, which are essential for ensuring product quality and patient safety.

Gemcitabine is included in the World Health Organization's Model List of Essential Medicines, highlighting its importance in a basic health system. The drug is also subject to international pharmacopoeia standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, gemcitabine is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for its sale. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including gemcitabine, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for gemcitabine have expired, leading to the availability of generic versions and increased competition in the market. This has resulted in more affordable treatment options for patients globally.

In July 2025, the FDA granted orphan drug designation to gemcitabine liposome injection for the treatment of biliary tract carcinomas, as per the FDA's Orphan Drug Designations and Approvals database. This designation aims to encourage the development of treatments for rare diseases by providing benefits like tax credits and market exclusivity.

In October 2023, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for gemcitabine-containing medicines to enhance safety information, as detailed in the EMA's periodic safety update report. This underscores the importance of continuous monitoring and updating of safety information for pharmaceuticals.

These developments reflect the dynamic regulatory landscape surrounding gemcitabine, emphasizing the need for manufacturers and exporters to stay informed and compliant with evolving standards and requirements.

India's pharmaceutical industry, renowned for its generic drug production, heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) synthesis. Approximately 60–70% of these critical inputs are imported from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese production or export policies can directly impact India's API manufacturing capabilities.

Recent geopolitical tensions have exacerbated these risks. In February 2026, the closure of the Strait of Hormuz disrupted the supply of raw materials to Asia's petrochemical industry, leading to production cutbacks and force majeure declarations. Such events underscore the fragility of the supply chain, where geopolitical conflicts can halt the flow of essential materials, affecting pharmaceutical production timelines and costs.

Our proprietary trade data indicates that the top five exporters of Gemcitabine from India account for 55.8% of the total export value, with FRESENIUS KABI ONCOLOGY LIMITED leading at 14.8%. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could significantly impact global Gemcitabine availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM production. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, reducing import dependence. While these initiatives are steps toward self-reliance, their impact on reducing supplier concentration in the Gemcitabine supply chain remains to be seen.

The closure of the Strait of Hormuz in February 2026 has had profound implications for global supply chains, including pharmaceuticals. Approximately 20% of the world's oil passes through this chokepoint, and its disruption has led to increased fuel prices and logistical challenges. Additionally, instability in the Red Sea and Suez Canal has forced shipping companies to reroute vessels around Africa's Cape of Good Hope, adding significant transit times and costs.

These disruptions have strained the pharmaceutical supply chain, leading to potential delays in Gemcitabine shipments from India to key markets like the United States and Europe. The FDA has been actively monitoring such situations to prevent and mitigate drug shortages, emphasizing the need for a resilient supply chain.

• Diversify KSM Sourcing: Reduce dependency on a single country by establishing alternative sources for KSMs, including domestic production and partnerships with other nations.

• Enhance Domestic Manufacturing: Accelerate the implementation of the PLI scheme to increase domestic production of APIs and KSMs, thereby reducing reliance on imports.

• Strengthen Supplier Networks: Expand the supplier base for Gemcitabine to mitigate risks associated with supplier concentration.

• Develop Contingency Plans: Establish robust contingency strategies to address potential geopolitical disruptions affecting shipping routes, ensuring timely delivery of pharmaceuticals.

• Monitor Regulatory Compliance: Regularly assess and ensure compliance with international quality standards to prevent regulatory actions that could disrupt supply chains.

RISK_LEVEL: MEDIUM